Get the Stockscreener App
2.25
0.45%
0.010
Pre-market:
2.22
-0.03
-1.33%
Zentalis Pharmaceuticals Inc stock is traded at $2.25, with a volume of 3.06M.
It is up +0.45% in the last 24 hours and down -25.00% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
See More
Previous Close:
$2.24
Open:
$2.26
24h Volume:
3.06M
Relative Volume:
2.21
Market Cap:
$160.35M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.4956
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
-14.93%
1M Performance:
-25.00%
6M Performance:
-39.19%
1Y Performance:
-82.54%
1-Day Range:
$2.19
$2.39
1-Week Range:
$2.16
$2.93
52-Week Range:
$2.16
$18.07
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.25 | 160.35M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Barclays PLC - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Down 17.5% in December - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - MarketBeat
Why Zentalis Pharma Is Worth Watching - RTTNews
Zentalis stock plunges to 52-week low of $2.64 amid market challenges - Investing.com Canada
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Zentalis Pharmaceuticals, Inc. Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies - Marketscreener.com
Zentalis Gets FDA Fast-Track Designation for Azenosertib - MarketWatch
Zentalis Pharmaceuticals Announces Azenosertib Fast Track - GlobeNewswire
Zentalis' Cancer Drug Azenosertib Receives FDA Fast Track Status for Ovarian Cancer Treatment - StockTitan
Geode Capital Management LLC Has $4.76 Million Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Barclays PLC Buys 11,748 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Jane Street Group LLC Sells 11,796 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals chief scientific officer sells $13,762 in stock By Investing.com - Investing.com South Africa
Mark Lackner Sells 4,411 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock - MarketBeat
Zentalis Pharmaceuticals chief scientific officer sells $13,762 in stock - Investing.com India
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Awards Stock Options to New Hires Under Incentive Plan - StockTitan
State Street Corp Sells 1,805,779 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Hold” by Analysts - Defense World
ZNTLZentalis Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Charles Schwab Investment Management Inc. Cuts Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Athersys (NASDAQ:ATHX) vs. Zentalis Pharmaceuticals (NASDAQ:ZNTL) Head to Head Review - Defense World
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm - Kilgore News Herald
Zentalis Pharmaceuticals expands leadership team - Investing.com India
Zentalis Pharmaceuticals Appoint Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer - citybiz
Zentalis Pharmaceuticals Announces Key Management Appointments - GlobeNewswire
Zentalis Pharmaceuticals Strengthens Leadership Team with Strategic Biotech Executive Appointments - StockTitan
The time has not yet come to remove your chips from the table: Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
Fmr LLC Has $18.68 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Osteosarcoma Market expected to rise | AlaMab Therapeutics, Zentalis Pharmaceuticals, Merck Eprova, Eisai Co Ltd., expected to drive Osteosarcoma market - Barchart
Osteosarcoma Market expected to rise | AlaMab Therapeutics, - openPR
Verition Fund Management LLC Buys 951,500 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals Grants 4.5M Stock Options to New CEO, CMO & Employees | ZNTL Stock News - StockTitan
ZNTL (Zentalis Pharmaceuticals) EBITDA : $-207.96 Mil (TTM As of Sep. 2024) - GuruFocus.com
Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $10.00 - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Sees Significant Drop in Short Interest - MarketBeat
Nano Dimension Leads 3 US Penny Stocks To Consider - Simply Wall St
Primecap Management Co. CA Boosts Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
What is HC Wainwright’s Forecast for ZNTL Q3 Earnings? - Defense World
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):